@CoulterPartners - Mar 5 Coulter Partners is delighted to be sponsoring BioCapital Europe, organised by LSP (Life Sciences Partners) once ag… https://t.co/PoH9PRUoW8
@CoulterPartners - Mar 5 RT @LifeSciRcruitr: We're off to a great start but could really use some more support. Please take a minute and consider a tax-deductible d…
Coulter Partners recently talked to Cristina Duran, Chief Digital Health Officer in R&D for AstraZeneca about digital disruption and talent in healthcare. "In other industries such as banking or retail, a focus on customers has always been key to the success of digital transformation. For pharmaceuticals it is the same. We focus on the patient and listen to what they want or need. We put the patient at the centre, listening to feedback on their experience of a clinical trial, for instance – the good and the bad. We are working together with patients and physicians in all our disease areas of focus to clarify the potential health outcomes of different treatment pathways."
"Medopad rebrands as Huma as it expands offerings and acquires AI and wearable tech startups." -
Coulter Partners talked recently to Tamir Strauss, Head of Customer Solutions at Huma about digital disruption and talent in healthcare: "I think if regulators were able to combine the fundamental need to keep patients safe with the understanding that the world of software development is evolving rapidly, then innovation would explode across all areas of this industry."
Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy. 
JOB HUNTING IN A PANDEMIC: To paraphrase the advice printed on the top of every one of those metal lids of Hellman's mayonnaise: "keep cool; do not freeze." Cute, but it turned out to be great advice, and a rule that I've reminded myself to follow whenever I've been faced with challenging situations.
“Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR 5 million” -
Coulter Partners recently talked to CEO and Co-Founder, Francois-Henri Boissel of Nova on digital disruption and talent in healthcare.
Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.
A selection of successful executive placements and new projects globally. Focus this quarter has been on Vaccines, Immunology, Gene Therapy, AI, CNS, Medical Implants, Diagnostics, Regenerative Medicine, Oncology and other areas. 
Coulter Partners talked recently to Karen Taylor, Research Director with the Deloitte Centre for Health Solutions, about Digital Disruption in Healthcare. "Digital Health providers need to do it with patients and not to patients," is key advice she would give them.
“Healx using artificial intelligence to find combination drug treatments for COVID-19” - Coulter Partners recently talked to Dr David Brown, Co-founder and Chairman of Healx, about digital disruption and talent in drug discovery.
“Digital front opens in war on Covid-19 as start-ups come to aid of NHS” “Video Consultations available to 5.3 million patients in Britain on the NHS” “Push Doctor aims to run online service in 500 practices by the end of 2020”
Coulter Partners recently talked to CEO, Wais Shaifta of Push Doctor on digital disruption and talent in healthcare.
“We are very pleased to welcome Melanie to our Board of Directors,” commented Dr Jean-Paul Kress, Chairman of the Board of ERYTECH Pharma. “We look forward to working with her to develop ERYTECH’s business plans and strategy as ERYTECH advances its late-stage clinical programs and begins preparations for its transition into a commercial-stage company. I would like to thank Coulter Partners for their professional support in achieving this high-caliber appointment”
Coulter Partners recently secured the appointment of Philip Lambert, PhD as Chief Scientific Officer for CENTOGENE (Nasdaq: CNTG) in Cambridge, MA . With more than two decades of experience in the global drug discovery and pre-clinical development sectors, Philip will have the overall responsibility of driving scientific programs to align with the needs of pharmaceutical partners.
Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S. subsidiary headquartered in Beverly, Massachusetts, providing American customers with direct sales and support, including a demo lab and training center.
Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.
Ian Churcher has 22 years’ experience in pharmaceutical R&D obtained in positions of increasing seniority in international companies including Merck Sharp & Dohme (Merck), GlaxoSmithKline (GSK) and BenevolentAI
Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.
A selection of senior appointments during Quarter 3, 2019 across EMEA. Industry segments this quarter included Artificial Intelligence, CNS, Animal Health, Immunology, Gene Therapy, Diagnostics, Precision Medicine, Vaccines and Antimicrobials.
Coulter Partners was delighted to partner recently with Azitra Inc. and secure the appointment of Mark Sampson, Ph.D. as their Chief Scientific Officer. Azitra is a clinical-stage medical dermatology company addressing severe skin conditions by harnessing the microbiome and has just announced that it has closed a $14 million Series A financing, led by KdT Ventures in conjunction with existing investor Bios Partners. 
Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”